Research Activity Sample Clauses

Research Activity. During each of Collaboration Years 5 and 6 of the Research Period, and subject to Monsanto’s timely [* * *], Evogene shall commence conducting no less than the minimum number of G2P Optimization Rounds for such Collaboration Year, under the Funded Project, each in respect of not less than the minimum number of Collaboration Hit Homolog and/or Special Collaboration Hits that shall enter such G2P Optimization Round, as set forth in subsections (a) and (b) below:
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Research Activity. During each of Collaboration Years 4 and 5 of the Research Period and subject to Monsanto’s timely provision to Evogene of the report set forth in Section 5.8, Evogene shall commence conducting not less than the minimum number of G2P Enhancement Rounds for such Collaboration Year, under the Funded Project, each in respect of a minimum number of Collaboration Hit Homologs that shall enter such G2P Enhancement Round, as set forth in Subsections (a) and (b) below: *** Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission.
Sample 1Sample 2Sample 3
Research Activity. During each of Collaboration Years 7 and 9 of the Research Period, Evogene shall commence conducting not less than that minimum number of G2P Enhancement Rounds for such Collaboration Year under the Fusarium Funded Project, pursuant to each of which Evogene shall deliver to Monsanto not less than the minimum number of Collaboration Hit G2P Data Backpacks, as set forth in subsections (a) and (b) below.
Sample 1Sample 2Sample 3
Research Activity. The research topic will be The research will be supervised by: (thesis supervisor at UNIBS) (thesis supervisor at the partner Institution)
Sample 1
Research Activity. The Instituto Superior de Ciencias Sociaise Poli'xxxxx (ISCSP) and the Central Asian Research Center (ORASAM) of the Kyrgyz-Turkish "Xxxxx" University conduct close cooperation on the fields of joint project, research activity and researchers mobility.
Sample 1
Research Activity. Research and analytical laboratory with related office function.
Sample 1
Research Activity. The premises shall be used for the purposes of offices ancillary to their life sciences research.
Sample 1
AutoNDA by SimpleDocs
Research Activity. Novel algorithms for the Direction-of-Arrival (DoA) estimation in radar and communication problems TOPIC The main research topic for this PhD program is represented by the estimation of the Direction-of-Arrival (DoA) of radio waves, specifically in non-cooperative environments and when no or little information is available at a radio receiver about the incoming signals. In these conditions the task typically relies on array processing, through the observation of the signal samples obtained at each antenna element. Such an estimate can be important on its own (for instance in direction finding applications, whose ultimate goal is to support the localization of an emitter) or be a part of a more general process aimed at optimizing reception in communication systems and detection and tracking performances in radars. Although this topic has a long history of research and relevant technological solutions, renewed interest and new trends have emerged in recent years, made possible by the diffusion of multi-channel Software-Defined-Radios (SDR) and by the development of novel DoA estimation algorithms. As for the latter, the effort of the research community is currently focused on the design of techniques (the majority belonging to the so-called family of subspace fitting methods) that can approach the statistical performances of the most complete parametric estimators, while maintaining a reduced computational complexity close to that of conventional spectral-based methods. The PhD research activity has thus the objective of refining and optimizing some of these novel estimation methods, in the following potential directions:  extension of their theoretical framework in order to cope with multiple dimensions and unknowns (azimuth, angle, frequency, range, polarization, etc.);  tailoring of the models for radio and radar applications of specific interest (e.g. direction finding in the HF spectrum);  implementation through suitable commercial-grade SDR architectures.
Sample 1
Research Activity 
Sample 1Sample 2Sample 3See All (5)

Related to Research Activity

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Term The term “

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Period The Contractor may commence pre-construction activities like utility shifting, boundary wall construction or any other activity assigned to the Contractor by the Authority to enable construction of the Project Highway immediately after signing of the Agreement, to the extent that such work is ready for execution. The Parties agree that these works may be taken up and completed to the extent feasible by the Contractor, before declaration of the Appointed Date, but no claim against the Authority for delay shall survive during this period and that the undertaking of these works by the Contractor shall not count towards the Scheduled Construction Period of the project which starts counting only from the Appointed Date. No construction activity of the Project Highway shall be undertaken during the development period.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

Time is Money Join Law Insider Premium to draft better contracts faster.